Nevertheless, despite its role in activating oncogenetic pathways, Rapamycin has also been considered a tumor-preventive agent since it delays carcinogenesis in tumor-prone p53+/− and p53−/− mice, most likely by slowing down the process of aging [46, 47]. Here, TP53 is linked to neoplasm.